1	Leveraging functional annotations to map rare
2	variants associated with Alzheimer's disease with
3	gruyere
4	Anjali Das ^{1,2} , Chirag Lakhani ² , Chloé Terwagne ³ ,
5	Jui-Shan T. Lin ² , Tatsuhiko Naito ^{2,4} , Towfique Raj ⁴ ,
6	David A. Knowles ^{$1,2,5,6^*$}
7	¹ Computer Science, Columbia University, New York, NY, USA.
8	² New York Genome Center, New York, NY, USA.
9	³ Francis Crick Institute, London, United Kingdom.
10	⁴ Neuroscience, Icahn School of Medicine, Mount Sinai, New York, NY,
11	USA.
12	⁵ Systems Biology, Columbia University, New York, NY, USA.
13	⁶ Data Science Institute, Columbia University, New York, NY, USA.
14	*Corresponding author(s). E-mail(s): dak2173@columbia.edu;
15	Contributing authors: anjali.das@columbia.edu;
16	clakhani@nygenome.org; chloe.terwagne@crick.ac.uk;

tlin@nygenome.org; tatsuhiko.naito@mssm.edu; towfique.raj@mssm.edu;

18

Abstract

The increasing availability of whole-genome sequencing (WGS) has begun to elu-19 cidate the contribution of rare variants (RVs), both coding and non-coding, to 20 complex disease. Multiple RV association tests are available to study the relation-21 ship between genotype and phenotype, but most are restricted to per-gene models 22 and do not fully leverage the availability of variant-level functional annotations. 23 We propose Genome-wide Rare Variant EnRichment Evaluation (gruyere), a 24 Bayesian probabilistic model that complements existing methods by learning 25 global, trait-specific weights for functional annotations to improve variant prior-26 itization. We apply gruyere to WGS data from the Alzheimer's Disease (AD) 27 Sequencing Project, consisting of 7,966 cases and 13,412 controls, to identify 28 AD-associated genes and annotations. Growing evidence suggests that disruption 29 of microglial regulation is a key contributor to AD risk, yet existing methods 30

1

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

> have not had sufficient power to examine rare non-coding effects that incorpo-31 rate such cell-type specific information. To address this gap, we 1) use predicted 32 enhancer and promoter regions in microglia and other potentially relevant cell 33 types (oligodendrocytes, astrocytes, and neurons) to define per-gene non-coding 34 RV test sets and 2) include cell-type specific variant effect predictions (VEPs) 35 as functional annotations. gruyere identifies 15 significant genetic associations 36 not detected by other RV methods and finds deep learning-based VEPs for splic-37 ing, transcription factor binding, and chromatin state are highly predictive of 38 functional non-coding RVs. Our study establishes a novel and robust framework 39 incorporating functional annotations, coding RVs, and cell-type associated non-40 coding RVs, to perform genome-wide association tests, uncovering AD-relevant 41 genes and annotations. 42

Keywords: Rare variants, Alzheimer's Disease, Bayesian probabilistic model,
 whole-genome sequencing

$_{45}$ 1 Main

The recent increase in available whole-genome sequencing (WGS) data has facilitated 46 the study of rare variants (RVs), particularly in understanding their effects on complex 47 diseases like late-onset Alzheimer's disease (AD). AD is a neurodegenerative disorder 48 with an estimated heritability between 59% and 74% [1]. While genome-wide associ-49 ation studies (GWAS) have identified over 100 loci linked to AD, with the APOE-e4 50 allele as the strongest genetic risk factor, they are restricted to common variant asso-51 ciations [2, 3]. Despite considerable efforts to quantify the polygenic nature of AD, a 52 significant portion of genetic heritability remains unaccounted for. Some of this miss-53 ing heritability may be recovered with RVs [4]. RVs generally exhibit larger effect sizes 54 than common variants, but their role is not yet well understood [5]. Studies have shown 55 that integrating RVs into cumulative polygenic risk scores (PRS) can enhance predic-56 tive performance [6], but existing methods have identified fewer gene associations and 57 have lower predictive power compared to common variant approaches. While a num-58 ber of genes, including TREM2, ABCA7 and SORL1 [7], have known RV associations 59 in AD, the majority of these findings are restricted to coding variants. As most GWAS 60 signals lie in the non-coding genome, expanding RV association studies beyond coding 61 variants is critical. However, the study of non-coding RVs poses challenges due to the 62 vast number of these variants, most of which likely have no functional impact [8]. It is 63 therefore of substantial interest to use functional annotations for variant filtering and 64 prioritization. To develop a more robust understanding of the contributions of both 65 coding and non-coding RVs to AD, we propose a novel method that not only weights 66 variants according to annotations but also prioritizes functional annotations that are 67 most trait-relevant. 68

Applying traditional variant-level approaches like GWAS to RVs has low statistical power due to sparsity and a high multiple testing burden due to the large number of RVs compared to common variants. To address these limitations, RV methods aggregate variants in biologically related regions, typically by gene, to increase power [9].

More recent RV methods additionally account for functional annotations to prioritize 73 relevant variants and filter out those predicted to have no function, which otherwise 74 reduce power [10, 11]. Despite growing efforts to accurately predict which variants will 75 affect particular molecular phenotypes (e.g., enhancer activation, RNA splicing) [12– 76 16], there is a limited understanding of *which functions* are the most disease-relevant. 77 Using functional annotations that have no phenotypic associations to weight RVs can 78 add noise to models and decrease their power. This motivated us to develop a method 79 that learns a genome-wide mapping from functional annotations to variant importance. 80 Growing evidence suggests that disrupted gene regulation in central nervous sys-81 tem (CNS) cell types, particularly microglia, is associated with the development and 82 progression of AD [1, 17]. The majority of RV tests are developed for coding variant 83 associations because 1) predicting functional coding variants is comparatively straight-84 forward (at least for loss-of-function), 2) population-scale whole-exome sequencing 85 predates WGS, and 3) defining non-coding regions for testing is challenging in itself. 86 Some methods use sliding windows, but testing overlapping windows of varying sizes 87 can result in loss of power due to multiple testing [18]. Other methods use predicted 88 cis-regulatory elements (CREs), in particular enhancers and promoters, to construct 89 testing regions [19–21]. Given their modest size (typically less than 2kb), testing indi-90 vidual CREs still has limited statistical power. Combining multiple CREs that regulate 91 a gene could help address this limitation but relies on accurate predictions of enhancer-92 gene links. We leverage the Activity-by-Contact (ABC) model, which predicts cell-type 93 specific enhancer-gene connectivity using chromatin state and conformation data [22]. 94 We aggregate ABC-predicted enhancer-gene pairs to determine non-coding, cell-type 95 and gene specific RV testing regions. 96

Due to the large number of genes and several million RVs found in population-scale 97 WGS, existing methods are primarily restricted to per-gene models. This limits our 98 understanding of disease-associated functional annotations. Most existing RV methqq ods are explicitly, or can be viewed as, generalized linear mixed models (GLMM). We 100 instead develop a Bayesian generalized linear model (GLM) Genome-wide Rare Vari-101 ant EnRichment Evaluation, or gruyere, to model cell-type specific, non-coding RV 102 associations on a genome-wide scale. In gruyere, a variant's effect is a deterministic 103 function of its annotations and the estimated AD-relevance of the gene it is linked 104 to (if any). Our Bayesian model iteratively learns AD-relevant gene effects, covariate 105 weights, and functional annotation importance while quantifying uncertainty, provid-106 ing increased flexibility to capture the complex, hierarchical structure of genetic data. 107 We test our model using simulation analyses and compare results to several existing RV 108 methods. We apply gruyere to WGS data from the Alzheimer's Disease Sequencing 109 Project (ADSP), consisting of 7,966 cases and 13,412 controls. Our model determines 110 splicing, transcription factor (TF) binding, and chromatin state annotations most 111 enriched for AD-associated non-coding RVs and identifies 16 significant genes, 15 of 112 113 which are uniquely identified by gruyere. Of these, four - C9orf78, MAF1, NUP93, and GALNT9 – remain significant in omnibus tests. 114

115 2 Results




Fig. 1 Overview of the application of gruyere to AD. Input data includes A) WGS and clinical information for AD cases and controls, B) Enhancer-gene interactions predicted by the ABC model for microglia, oligodendrocytes, astrocytes, and neurons, and C) variant functional annotations. D) Example analysis for the *TREM2* gene and microglia cell-type on existing methods. Columns represent RVs; light grey rectangles represent individual-level genotypes from WGS data for cases and controls; functional annotations for each RV are shown below genotypes; Burden, SKAT, SKAT-O, and ACAT-O are existing tests that use genotype, covariate, and AD status; FST and STAAR-O additionally use functional annotations. E) Workflow for gruyere. Per-gene RVs are aggregated and used for fitting the hierarchical Bayesian GLM. gruyere learns weights for covariates, genes, and functional annotations. We use simulations to assess gruyere at different heritabilities. Likelihood ratio tests are used to calculate gene-level *p*-values. Optionally, the gruyere *p*-values can be integrated with existing methods through omnibus testing.

2.1 Genome-wide Rare Variant EnRichment Evaluation (gruyere) overview

Variable	Shape	Description
Y	$n \ge 1$	Phenotypes for n samples
X	$n\ge c$	c Covariates for n samples
G_g	$n \ge p_g$	Genotypes for p variants in gene g for n samples
Z_g	$p_g \ge q$	q Functional annotations for p variants in gene g
α_g	$c \ge 1$	c Covariate coefficients
β_{gj}	$p_g \ge 1$	Variant effect sizes for p variants in gene g
w_j	$p_g \ge 1$	Variant weight $Beta(MAF_j 1, 25)$
w_g	1 x 1	Gene importance weights
τ	$q \ge 1$	Functional annotation weight

 Table 1
 Summary of gruyere Variables

Current RV methods rely on independent per-gene models and, therefore, cannot capture genome-wide functional annotation importance. **gruyere** serves as a complementary method to existing RV tests by learning trait-specific functional annotation weights, covariate coefficients, and gene effects under a Bayesian framework (Supplemental Figure 1, Table 1). Rather than modeling each gene separately, we jointly fit **gruyere** as a hierarchy of per-gene GLMs using stochastic variational inference (SVI) [23]. We model AD risk for each gene q,

$$\operatorname{logit}(\mu_{ig}) = X_i \alpha_g + G_{ig} \beta_{gj}$$

where μ_{ig} is the probability of AD for individual *i* given the genotypes for RVs associated with gene *g*, X_i is a vector of covariates (e.g. sex, age, *APOE-e4* genotype), and G_{ig} is a genotype vector. We learn covariate weights α_g and variant effects β_{gj} . We set β_{gj} to be a deterministic function of a learned gene effect w_g , transformed minor allele frequencies (MAFs) w_j , functional annotations *Z* (detailed in Methods 3.4 and Figure 1C), and learned annotation importance weights τ ,

$$\beta_{gj} = w_g w_j (\tau_0 + \sum_{k=1}^q Z_{gjk} \tau_k).$$

In our analyses, gruyere learns annotation weights τ for a range of annotations Z. 118 including in silico mutagenesis deep learning model predictions of splicing disruption 119 (derived as the maximum of four individual SpliceAI scores [24]) and cell-type specific 120 TF binding and chromatin state (derived from the Enformer model [14]). A larger 121 magnitude of w_q indicates that disruption of gene g is associated with a higher pre-122 dicted risk of AD. Similar to a burden test, gruyere assumes all variants within a gene 123 have the same direction of effect [25, 26]. However, because our functional annotations 124 include both loss- and gain-of-function predictions, we are able to capture additional 125 dispersion-based signal. To ensure robust generalization of learned parameters, we 126 split data into training (80%) and test (20%) sets, where model weights are optimized 127 using the training set and assessed on the unseen test set. We apply gruyere to both 128 coding and non-coding RVs for AD, defining four cell-type specific non-coding groups 129 for AD-relevant cell types (microglia, oligodendrocytes, astrocytes, and neurons [17]) 130 and testing each group individually. 131

132 Step 1. Estimating global annotation weights τ .

Fitting τ jointly across the entire genome would be 1) computationally challenging 133 due to the large number of RVs and 2) statistically inefficient, as only AD-associated 134 genes will contribute relevant signal. We therefore estimate τ under the gruyere model 135 from a subset of potentially AD-relevant genes identified using a lenient significance 136 threshold (nominal p < 0.01) for the Functional Score Test (FST)[27]. We assess 137 the robustness of gruyere estimates when selecting genes with varied significance 138 thresholds and for a number of existing RV tests and find annotation weights τ are 139 broadly consistent (+/-0.02). 140

¹⁴¹ Step 2. Per-gene analysis.

Once genome-wide estimates for τ are obtained, gruyere simplifies to a logistic regression that learns covariate α_g and gene w_g weights. We efficiently fit gruyere separately and in parallel for all genes, holding τ fixed. We perform likelihood ratio tests (LRT) to compare a covariate-only regression against combined covariate and genotype regression models to determine gene-level significance for w_q .

¹⁴⁷ 2.2 Constructing cell-type & gene specific variant sets using ¹⁴⁸ predicted CREs




Fig. 2 Predicted regulatory element and variant counts across cell types. A) Bar plot of predicted CRE counts by cell type (ABC > 0.02). B) Upset plot of variant overlap across 4 cell types in ADSP data; Light grey bars on left indicate total RV counts for each cell type; Vertically connected dots represents groups and corresponding bars indicate variant overlap for that group.

We grouped non-coding RVs by gene and CNS cell type using the Activity-by-149 Contact (ABC) model (Figure 1B) [22]. The ABC model uses epigenomic profiles and 150 chromatin conformation to determine cell-type specific enhancer-gene interactions, 151 filtering out genes that are not expressed. We use publicly available ATAC-seq and 152 H3K27ac ChIP-seq signals for microglia, oligodendrocytes, astrocytes, and neurons 153 [28], as well as Hi-C averaged across ten CNS cell types to account for 3-dimensional 154 chromatin interactions. For each gene, we analyze RVs aggregated across all CREs 155 interacting with that gene (ABC > 0.02). We test each cell type separately and also 156 analyze rare coding variants for comparison. In total, ABC defines 70,300 CREs across 157 all four cell types and 17,929 genes, with higher relative counts of microglia-predicted 158 enhancers (Figure 2A). Predicted CREs frequently co-occur across cell types, with 159 39.4% of CREs found in more than one cell type. Promoter regions tend to have higher 160 ABC scores than enhancers (mean ABC = 0.07 vs. mean ABC = 0.04), but their 161 genomic lengths are similar, with an average length of 632bp and standard deviation 162 of 132bp. ABC accounts for interactions of a single enhancer with multiple genes so 163 one RV can be linked to multiple genes. In our analysis, an ABC enhancer maps to 164 an average of 3.8 genes in microglia and between 5.4 and 5.9 genes in the other three 165 cell types. Our non-coding variant sets contain an average of 376 RVs per gene. There 166 are a total of 2,092,931 RVs in CREs across the four cell types, 901,570 of which are 167

6

included for more than one cell type, and 550,001 that are in all four cell types (Figure 2B).

2.3 Simulation studies confirm accurate estimation of model parameters

We generate synthetic phenotypes (see Methods 3.5) and fit gruyere on 100 sets of 172 simulated data with estimated heritability between 5% and 30% (detailed in Supple-173 mental Methods [29]) using 500 randomly selected genes. We find that all variables 174 are well recovered, with average Pearson correlations R = 0.81, 0.95, 0.98, 0.97 for 175 $\alpha_q, \beta_{qj}, w_q$ and τ respectively (Figure 3). Covariates α_q have the lowest R, possibly 176 due to correlated covariates. Average recovery across all variables remains high when 177 varying the prior distributions (Pearson R > 0.78) as well as when simulated distri-178 butions differ from the priors used during inference (Pearson R > 0.66). Results are 179 robust to the number of covariates, genes, and annotations modeled. 180




Fig. 3 Learned versus true gruyere parameters across 100 simulations. Points are colored by the Pearson correlation coefficient of a parameter for a given simulation. A) Covariate regression coefficients α (c = 30 covariates). B) Variant effect β . C) Gene effect w_g (M = 500 randomly selected genes). D) Annotation weight τ (q = 13 annotations).

¹⁸¹ We analyze how simulation performance correlates with overall and genetic her-¹⁸² itability for each simulation. This allows us to more meaningfully evaluate model ¹⁸³ performance for complex diseases like AD where estimated heritability is low. As ¹⁸⁴ expected, we find that gruyere is better able to recover β_{gj} and w_g with increased ¹⁸⁵ genetic heritability (Supplemental Figure 2). However, even when total heritability

> is as low as 5%, the minimum correlation between true and estimated parameters remains quite high (Pearson R = 0.68).

2.4 Applying gruyere to AD WGS data reveals novel disease associations




Fig. 4 Performance of gruyere. A) Boxplots of per-gene AUROCs for train and test sets across cell types. B) Boxplots of per-gene accuracies for train and test sets across cell types. C) Trace ELBO loss over 300 epochs across cell types. D) Average training time per epoch (seconds) versus number of genes used in joint model for each cell type.

Performance on ADSP WGS data. After validating model performance through 190 simulations, we fit gruyere to the ADSP WGS data. We analyze coding and non-191 coding (microglia, oligodendrocyte, neuron, astrocyte) groups separately, and refer to 192 each set as a cell type. For each cell type, we use a subset of genes for joint fitting 193 (FST p-value < 0.01), leading to between 267 and 333 genes per cell-type. AD predic-194 tion performance is fairly consistent across non-coding variants (average test set Area 195 Under the Receiver Operating Characteristic, or AUROC, of 0.69) and slightly higher 196 for coding variants (average $AUROC_{\text{test}} = 0.70$) (Figure 4A-B). When averaging pre-197 dicted probabilities across genes, performance further improves $(AUROC_{\text{test}} = 0.72)$ 198 for all cell types. These metrics are in line with current AD literature and outperform 199 a covariate-only regression model ($AUROC_{\text{test}} = 0.65$) [30]. There is a substantial 200 range in prediction performance for each cell type (e.g. minimum $AUROC_{\text{test}} = 0.62$, 201 maximum $AUROC_{\text{test}} = 0.71$ for microglia), highlighting the varying degrees of asso-202 ciation with AD across genes. We find that gene-level performance is consistent across 203 model refitting and that the loss converges reliably (4C) [31]. Fitting time increases 204

²⁰⁵ approximately logarithmically with the total number of genes (Figure 4D). On aver-

age, it takes 37 seconds per epoch and three hours total to jointly fit gruyere across
300 epochs. Per-gene estimation is much faster, taking an average of 4.3 seconds per

208 gene to complete.




Fig. 5 gruyere parameters learned from ADSP WGS. A) Bar plot of genome-wide annotation weights τ learned in jointly fit model across cell types. We denote crosses (X) to the left of bars where an annotation is not included for a cell type. B) Bar plot of per-gene covariate weights (α_g) learned in jointly fit model across cell types. Error bars illustrate the minimum and maximum values learned across genes.

Learned annotation and covariate weights. We find that the top gruyere 209 functional annotation weights come from splicing across all non-coding RV groups and 210 loss-of-function (LoF) for coding variants (Figure 5A). LoF variants can be highly 211 disruptive to gene function and are often used as a variant filtering method in gene-212 based tests. Therefore, it is predictable that we find gruyere places a large weight 213 on LoF coding RVs. It is perhaps not surprising that gruyere also prioritizes RVs 214 predicted to disrupt normal splicing, as they can substantially change the protein 215 product or have large effects on gene dosage via nonsense mediated decay. For all 216 non-coding regions, cell-type specific TF binding predictions from Enformer contain 217 the next largest annotation weights. This suggests RVs associated with an increase 218 (Max TF Delta) or decrease (Min TF Delta) in binding are predicted to have larger 219 effects on AD, at least in AD-relevant genes. For microglia RV sets, we additionally 220 find increased AD association for variants related to histone modification (H3K4me3, 221 H3K27me3, H3K27ac) and DNASE in monocytes (often used as a proxy for microglia 222 [32]). We restrict Enformer annotations to non-coding variants as they are specific 223 to cell-types. The enhancer category has very small weights across cell-types. Since 224 all variants included in the non-coding analyses are in putative CREs, it is perhaps 225 not too surprising that cell-type specific enhancer annotations are lowly prioritized by 226 gruyere. 227

Covariate effects are learned consistently across genes and cell types, with sequencing center, common variant polygenic risk score, and Illumina HiSeq 2000 sequencing platform as the top three covariates (Figure 5B). As expected, *APOE-e4* is learned to have a large positive risk effect while the *APOE-e2* allele has a negative (protective) effect [2]. These effects agree well with those of a simple logistic regression predicting AD status from covariates.




Fig. 6 Top gruyere genes. A) Manhattan plot across cell types. The Y-axis shows $-\log_{10}(p\text{-value})$ for each gene and X-axis shows gene position. Each color is a cell type. gruyere-significant genes are labeled. B) Stacked upset plot of significant gene overlap across all tests after pruning for coregulation. Dark grey bars on left indicate total number of significant genes for each test. Vertically connected dots represent groups and corresponding bars indicate the number of overlapping significant genes identified for that group. Each bar is colored by cell type.

Learned gene effects and associations: Estimated gene effects w_q are fit from 234 a per-gene logistic regression, where we use LRTs to determine gene-level gruyere p-235 values (Methods 3.2). Significant genes after Bonferroni correction for each cell type 236 are shown in Figure 6A, where a total of 16 genes reach genome-wide significance. 237 The well-established TREM2 RV association [33], as well as MAF1, C9orf78, and 238 GRIK3 are found significant for coding variants. Although not as widely recognized as 239 TREM2, MAF1 has been previously reported in association with AD [34], and C9orf78 240 has been identified in an AD dementia meta-analysis [35]. GRIK3 has emerged as a 241 gene of interest due to the role of kainate receptors in neuroinflamation, a key feature 242 of AD. Inflammatory responses can amplify glutamate release and disrupt receptor 243 functioning, which may further accelerate neurodegeneration. This makes GRIK3, 244 and glutamate signaling more broadly, potential targets for therapies [36, 37]. The 245 identification of these genes by gruyere highlights their potential as candidate genes 246 for further study in AD. 247

gruyere identified 12 non-coding RV associations across cell types with 2 in microglia, 6 in astrocytes, 1 in neurons, and 3 in oligodendrocytes. The most significant of these is *NUP93* (microglia), which, although not specifically linked to AD, is part of a group of nucleoporin (Nup) mutations associated with neurodegenerative disorders like AD [38]. Three significant genes, *GALNT9*, *FBRSL1*, and *LOC101928416*, are closely located on chromosome 12q24.33 and share over 80% of their ABC-predicted CREs, indicating that their associations are driven by the same set of RVs. Although

variants can map to multiple genes in our model framework, making our analysis sus-255 ceptible to coregulation, we are able to investigate and identify the specific CREs 256 driving these associations. Of the overlapping promoters for these three genes, regions 257 have higher ABC scores for FBRSL1 (ABC = 0.20) compared to GALNT9 (ABC = 258 (0.04) and LOC101928416 (ABC = 0.06), suggesting a stronger regulatory impact on 259 FBRSL1 and further isolating overlapping signal. FBRSL1 (neuron), has not been 260 linked to AD, but it presents a strong candidate gene for its distinctive neuronal expres-261 sion profile and involvement in neurogenesis and transcriptional regulatory networks 262 [39]. Multiple associations (GALNT18, CTR9, EIF4G2, ZBED5-AS1, LOC101928053, 263 and *MRVI1*) specific to astrocyte and oligodendrocyte cell-types are coregulated in 264 chromosome 11p15.4, and the strongest signal, GALNT18, has been connected to AD 265 in more than one study [40, 41]. After pruning coregulated signals, gruyere identifies 266 8 significant genes. 267

We identify both known and novel AD-associated risk genes with gruyere. Sig-268 nificant gruyere genes are associated with increased gene expression across thirteen 269 brain tissues found in GTEx (2-sample t-test $p = 9.2 \times 10^{-31}$, Supplemental Figure 270 3A) [42]. 5 of our 16 significant genes have expression QTLs in our microglia genomic 271 atlas (isoMiGA) that colocalize with AD or Parkinson's disease (PD) GWAS (Sup-272 plemental Figure 3B) [43–46]. Specifically, TREM2 and MAF1 have significant SNPs 273 in a recent AD GWAS [44] while *FBRSL1*, *EIF4G2*, and *ZBED5-AS1* are signifi-274 cant in a large PD GWAS [45]. AD and PD have known genetic overlap, motivating 275 QTL colocalization of both traits [47]. Finally, we compare gruyere *p*-values with the 276 Alzheimer's Disease Variant Portal (ADVP) catalog of 956 reported AD genes, find-277 ing that gruyere yields more significant p-values for ADVP versus non-ADVP genes 278 (2-sample t-test $p = 7.1 \times 10^{-9}$, Supplemental Figure 3C) [48]. 279

²⁸⁰ Comparing gruyere to existing methods.

We compare pruned gruyere results with AD associations identified by a number of 281 existing RV methods: burden test, sequence kernel association test (SKAT), optimal 282 unified test (SKAT-O), functional score test (FST), aggregated Cauchy association test 283 (ACAT), and variant-set test for association using annotation information (STAAR) 284 [10, 25, 27, 49–51]. Burden, SKAT, SKAT-O, and ACAT-O tests do not include 285 functional annotations, while FST and STAAR incorporate them (description in Sup-286 plemental Table 1 and detailed in Figure 1D for *TREM2* and microglia). We use the 287 same set of functional annotations for FST and STAAR as for gruyere. We find that 288 gruyere $-log_{10}(p$ -values) have the highest correlation with Burden tests (Pearson 289 R = 0.86) and show moderate to high correlation with combination methods STAAR-290 O, SKAT-O, FST, and ACAT-O (Pearson R = 0.45 - 0.58) (Supplemental Figure 291 4A). The higher observed correlation with burden tests is expected, as gruyere also 292 assumes unidirectional variant effects within a gene. We examine overlap of significant 293 genes across all tests and find that there is minimal overlapping signal across meth-294 ods (Figure 6B). Of the 16 (8 pruned) AD associations identified by gruyere, 15 (7 295 pruned) are unique to gruyere, while TREM2 (coding) is detected across all tests but 296 SKAT where it narrowly misses significance. In total, burden, SKAT, SKAT-O, and 297

> ACAT-O tests identify only two significant associations, highlighting the importance of including functional annotations, particularly for non-coding RV associations.

> Integrating gruyere into omnibus tests. We combine gruyere *p*-values with 300 existing methods using ACAT (Supplemental Figure 4B). Comparing ACAT (burden, 301 SKAT, SKAT-O, FST, ACAT, STAAR) to ACAT(gruyere, burden, SKAT, SKAT-302 O, FST, ACAT, STAAR), we find that the inclusion of gruyere in omnibus tests 303 boosts the number of significant associations from 12 to 16, adding C9orf78, MAF1, 304 NUP93 and GALNT9. There is no loss of power with this method, as all existing 305 signals remain after including gruyere; we simply increase the total number of AD 306 associations identified. 307

$_{308}$ 3 Methods

309 3.1 Data Overview

Whole-Genome Sequencing Data: We analyze the latest release of WGS data 310 from the Alzheimer's disease sequencing project (ADSP) consisting of 21.378 unre-311 lated individuals over the age of 65 (7,966 cases, 13,412 controls) after QC [52?]. We 312 follow a standard pipeline to QC WGS data. First, we combine phenotype information 313 across multiple cohorts and remove genetically identical duplicates (IBD $\hat{\pi} > 0.95$) and 314 technical replicate samples, selecting samples with the highest call rates. We priori-315 tize phenotype information for individuals in family studies over case-control studies. 316 Related individuals are removed using Kinship-based INference for Gwas (KING) [53], 317 keeping AD cases where possible. In PLINK [54], we remove individuals with more 318 than 10% genotype missingness, variants with less than 90% genotyping rate, and 319 keep only biallelic variants with an observed $MAF \leq 0.05$. Missing genotypes are 320 imputed as the average observed MAF. For analysis, we randomly split samples into 321 80% train and 20% unseen test sets, stratifying by ancestry. ADSP samples are pri-322 marily of European (N = 9.133), African (N = 5.173) and Hispanic (5.059) ancestry, 323 with smaller South Asian (N = 1.951) and East Asian (N = 62) groups. 324

Clinical Information: We use 30 available covariates in our model: sex, age, age², age × sex, age × sex², APOE-e4 genotype, APOE-e2 genotype, 10 ancestry principal components calculated from the 1000 Genomes Project [55], a common variant PRS [56], one-hot encoded sequencing platform (Illumina HiSeq 2000, HiSeqX, Nova Seq), one-hot encoded sequencing center (Illumina, USUHS, USUHS/Miami, NYGC, MEDGENOME, Baylor, Broad, WashU), and an intercept term (Figure 1A).
Covariates are min-max scaled to a range of 0 to 1.

332 3.2 Proposed Bayesian rare variant model: gruyere

We develop **gruyere**, a hierarchy of per-gene GLMs (Supplemental Figure 1). We define our model jointly as

$$\operatorname{logit}(\mu_{ig}) = X_i \alpha_g + G_{ig} \beta_{gj}$$

where μ_{ig} is the probability of AD for individual *i* associated with gene *g*, X_i is a vector of covariates, and G_{ig} is a vector of genotype dosages for each RV. Covariate coefficients α_g are modeled from prior,

$$\alpha_g \sim \text{Normal}(0, 1).$$

The key innovation in the **gruyere** model is the construction of per-variant genetic effects for gene g, or $\beta_{gj} = (\beta_{gj1}, ..., \beta_{gjp})^T$, which is defined as the product of gene effects, transformed MAF, and weighted functional annotations. Of note, if a variant j is included in the RV set for both genes g_1 and g_2 , the variant effect can differ for β_{g_1j} and β_{g_2j} . We define β_{gj} as

$$\beta_{gj} = w_g w_j (\tau_0 + \sum_{k=1}^q Z_{gjk} \tau_k)$$

where w_g are gene importance weights, w_j are variant weights based on observed MAF as suggested by Wu et al.[49], τ are genome-wide annotation importance scores, and Z_{gjk} is a scaled functional annotation k for RV j and gene g. The variables are modeled as,

$$w_j = \text{Beta}(MAF_j|1, 25)$$

 $w_g \sim \text{Normal}(0, 1)$
 $\tau \sim \text{Dirichlet}(\mathbf{1}_q)$

For each gene, we use a Bernoulli likelihood to sample $\sigma(X_i \alpha_g + G_{ig} \beta_{gj})$, and aggregate loss across each $g \in M$. Learned parameters are α_g, w_g , and τ . We select a Dirichlet prior for annotation weights τ to ensure identifiability between τ and w_g . Without constraining τ to a fixed sum, w_g can be swapped for w_g/c and τ for $c\tau$ for any positive constant c without changing the likelihood, leading to non-identifiability between gene and annotation weights.

We approximate the true posterior distribution for gruyere by minimizing the 339 Kullback-Leibler (KL) divergence, which is equivalent to maximizing the Evidence 340 Lower Bound (ELBO) [31]. To maximize the ELBO, we use SVI, implemented in the 341 pyro probabilistic programming language [57]. We approximate the posterior distribu-342 tion of latent variables α_q and w_q with mean field normal distributions (AutoNormal 343 guide), while optimizing annotation weights τ as point estimates with a Delta distri-344 bution (AutoDelta guide). We apply the Adam optimizer, a learning rate of 0.1, train 345 for 300 epochs, and draw 50 samples from the posterior to estimate standard devi-346 ations of the learned parameters. We explore different prior distributions for all key 347 parameters. 348

Once global τ is learned, we streamline gruyere with a per-gene analysis. Holding τ fixed, our model simplifies to a logistic regression where only α_g and w_g are estimated. gruyere efficiently computes gene-level *p*-values using LRTs comparing a covariateonly regression to a combined covariate and genotype regression model:

$$LR_g = -2 \times (LL_{\text{combined}_g} - LL_{\text{covariate only}}), \quad df = 1$$

gruyere p-value $(g) = P(\chi^2 > LR_g)$

where LL are the log-likelihoods for each logistic regression. For each cell type, we use Bonferroni correction to define the p-value significance threshold:

 $p < \frac{0.05}{\# \text{ genes per cell type}} \Rightarrow 2.88 \times 10^{-6} < p < 3.64 \times 10^{-6}$

353 3.3 Cell-type specific RV gene set prediction using the ABC model

We calculate enhancer-gene connectivity using publicly available ATAC-seq and 355 H3K27ac ChIP-seq data for human microglia, oligodendrocytes, astrocytes, and 356 neurons [28]. We apply ABC to this data following the guidelines and default parame-357 ters provided at https://github.com/broadinstitute/ABC-Enhancer-Gene-Prediction. 358 This involves first calling candidate peak regions for the ATAC-seq DNase hypersen-359 sitive sites (DHS) using MACS2 (peakExtendFromSummit = 250, nStrongestPeaks =360 150000). Then we quantify enhancer activity as the geometric mean of the read counts 361 of DHS and H3K27ac ChIP-seq in candidate enhancer regions. Lastly, we compute 362 the ABC score using averaged Hi-C data (hic_resolution = 5000) fit to the power-law 363 model. The omics data is aligned to hg19, so we converted the ABC-predicted start 364 and end positions of enhancers to hg38 for analysis. For each gene and separately 365 each cell type, we aggregate all elements E for gene G that have an $ABC \geq 0.02$ and 366 extract RVs from within these regions to determine our cell-type specific non-coding 367 RV gene sets. 368

³⁶⁹ 3.4 Calculating functional annotation groups

We use a range of variant-level functional annotations primarily from the Whole 370 Genome Sequencing Annotation database [58]. Annotations with greater than 5%371 missingness in our RVs are removed, resulting in 50 coding variant and 52 non-coding 372 variant functional annotations listed in Supplemental Table 2. To reduce dimensional-373 ity of related annotations while accounting for their diverse biological effects, we apply 374 non-negative matrix factorization (NMF) to summarize groups of related annotations, 375 inspired by STAAR [10]. We use NMF to retain interpretable directional scaling of 376 annotations. Based on correlation structure and a priori knowledge, we define six 377 major functional categories - splicing, conservation, integrative deleterious predictions, 378 brain-related Roadmap epigenetics, population-specific MAF, and enhancer activity 379 [15, 59, 60]. Because the splicing annotation group is derived from four SpliceAI pre-380 dictions that are not highly correlated and sparsely distributed, we instead use the 381 maximum score for this category. We also include a binary LoF prediction calculated 382 with Loss-Of-Function Transcript Effect Estimator (LOFTEE) [61] for coding vari-383 ants along with an intercept term. All annotations are scaled between 0 and 1, where 384 a larger value represents increased predicted variant function. 385

386 Deep Learning Delta Scores: For all four cell types, we include additional cell-

 $_{\tt 387}$ type specific functional annotations: absolute maximum and absolute minimum TF

delta scores derived from Enformer [14], a deep learning genomics model. We calculate

variant delta scores for 5,318 functional genomics assays. The Enformer model predicts 389 read counts (in 128 BP bins) of these assays as a function of 196,608 BP input DNA 390 sequence. For a particular variant, we compare the model output of the reference 391 sequence, centered around the variant position, with the output of the alternative 392 sequence which replaces the reference allele with the alternative allele. For a particular 393 genomics assay, the delta score is the difference between the sum of reference sequence 394 predictions for the middle 32 bins and the sum of the alternate sequence predictions 395 for the same bins. We normalize these scores by first calculating the delta scores for 396 the approximately 18 million variants from the UK Biobank cohort used in PolyFun 397 [62, 63], and then Z-score normalize each assay according based on this collection of 398 variants. We apply this normalization to the delta scores used in our analysis. We aggregate delta scores to determine composite maximum and minimum predictions 400 for each variant, highlighting the delta scores of only the enriched TFs within each of 401 the four cell types ([28]). For microglia non-coding variant sets, we additionally use 402 delta scores for 4 epigenetic marks (H3K4me3, H3K27ac, H3K27me3, and DNASE) 403 for monocytes, a proxy for microglia. 404

405 3.5 Data Simulation

We use simulations to evaluate **gruyere** performance. We randomly sample values for each parameter and use these simulated variables in the GLM framework, $logit(\mu_{ig}) = X_i \alpha_g + G_{ig} \beta_g$. The real ADSP genotypes G_{ig} , covariates X_i , and functional annotations Z_{gjk} along with simulated parameters α_g^S, w_g^S , and τ^S , generate simulated phenotypes Y_{ig}^S . Simulations are restricted to a maximum estimated heritability of 30% to realistically evaluate complex diseases. For each simulation, we draw **gruyere** parameters from the following distributions:

 $\alpha_g^S \sim \text{Normal}(0,1), \quad w_g^S \sim \text{Normal}(0,1), \quad \tau^S \sim \text{Dirichlet}(\mathbf{1}_q)$

We define β_{gj} in the same way, simply using simulated variables:

$$\beta_{gj}^S = w_g^S w_j \sum_{k=1}^q Z_{gjk} \tau_k^S$$

Using this combination of true data and simulated parameters, we sample synthetic phenotypes y_g^S from a Bernoulli distribution. We perform 100 simulations on M =500 randomly selected genes. In general, we sample **gruyere** parameters from the same distribution that they are learned. We have also tested model performance when simulated data comes from a different distribution than its learned counterpart (e.g. sampling w_g from a Normal distribution in simulations but fitting from a Gamma prior).

413 4 Discussion

⁴¹⁴ We develop **gruyere**, a functionally-informed RV association test that fits a hierar-⁴¹⁵ chy of Bayesian GLMs to estimate genome-wide functional annotation importance,

> gene effects, and covariate coefficients. gruyere builds upon existing RV methods with 416 two key advancements: 1) a genome-wide approach that enables trait-specific weight-417 ing of functional annotations, and 2) a flexible, powerful and calibrated probabilistic 418 framework that estimates uncertainty. We incorporate an innovative methodology for 419 analyzing RVs in the non-coding genome. Using the Activity-by-Contact model, we 420 predict cell-type-specific enhancer-gene connectivity from chromatin state and con-421 formation data, aggregating predictions by gene to define interpretable non-coding 422 RV testing regions. We use in silico mutagenesis under state-of-the-art deep learning 423 models of pre (SpliceAI) and post (Enformer) transcription gene regulation to pre-424 dict RV effects. Simulation analyses validate gruyere and show it is able to recover 425 ground truth parameters across diverse model specifications and even for realistically 426 low heritability. 427

> We apply gruyere, along with a number of established RV association tools, to 428 the most recent WGS release from ADSP. Our analysis identifies both known (e.g., 429 TREM2) and novel (e.g., NUP93) candidate AD genes. Specifically, gruyere uniquely 430 identifies 15 genes, of which C9orf78, MAF1, NUP93 and GALNT9 remain signif-431 icant in aggregated Cauchy tests. Our analysis additionally provides an improved 432 understanding of AD-relevant functional annotations. gruyere confirms the expecta-433 tion that LoF is the most informative annotation for coding variants, but additionally 434 finds deep learning-based predictions for splicing, TF binding and chromatin state are 435 highly predictive of functional non-coding RVs. 436

> We use ancestry principal components as covariates to account for population 437 diversity, but one area for future work would be integrating a random effect term to 438 better account for relatedness and population structure [64]. Another possible exten-439 sion to gruyere would be incorporating gene-level features as priors [65]. While we 440 focus our analysis on AD, gruyere can be applied to any complex disease with suf-441 ficient WGS data. As the quality of functional annotations continues to improve, 442 gruyere will become an increasingly valuable tool for identifying disease-associated 443 genes and annotations. 444

Supplementary information. Supplementary Figures 1-4; Supplementary Table
1-2; Supplementary Methods; Supplementary Acknowledgements; Supplementary
Data: Gene *p*-values for each cell-type.

Acknowledgements. Research reported in this paper was supported by Alzheimer's Disease Sequencing Project of the National Institutes of Health under award number 5 U01 AG068880-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We are thankful to Tulsi Patel, Edoardo Marcora, Alison Goate, and Iuliana Ionita-Laza for helpful feedback and discussions.

454 Declarations

- Funding: Research reported in this paper was supported by Alzheimer's Disease
 Sequencing Project of the National Institutes of Health under award number 5 U01
 AG068880-02.
- Declaration of interests: T.R. served as a scientific advisor for Merck and serves as a consultant for Curie.Bio.
- Ethics approval and consent to participate: Not applicable
- ⁴⁶¹ Consent for publication: Not applicable
- Data availability: This paper uses the ADSP Release 4 WGS data and AD phenotype data.
- Materials availability: Not applicable
- Code availability: Code and details for running gruyere is available on GitHub: https://github.com/daklab/gruyere
- Author contribution: D.A.K. conceived and supervised the project. A.D. and D.A.K.
- developed the methods. A.D. and D.A.K. wrote the manuscript. A.D. wrote the software code and performed the analyses. All authors read, reviewed, and approved
- the final manuscript.
- 471 Editorial Policies for:
- 472 Springer journals and proceedings: https://www.springer.com/gp/editorial-policies
- 473 Nature Portfolio journals: https://www.nature.com/nature-research/editorial-policies
- 474 Scientific Reports: https://www.nature.com/srep/journal-policies/editorial-policies
- 475 BMC journals: https://www.biomedcentral.com/getpublished/editorial-policies

476 **References**

[1] Sims, R., Hill, M., Williams, J.: The multiplex model of the genetics of alzheimer's disease. Nat. Neurosci. 23, 311–322 (2020) https://doi.org/10.1038/
 s41593-020-0599-5

- [2] Andrews, S.J., Renton, A.E., Fulton-Howard, B., Podlesny-Drabiniok, A., Marcora, E., Goate, A.M.: The complex genetic architecture of alzheimer's disease:
 novel insights and future directions 90, 104511 (2023) https://doi.org/10.1016/j.
 ebiom.2023.104511
- [3] Auer, P.L., Lettre, G.: Rare variant association studies: considerations, challenges
 and opportunities 7, 16 (2015) https://doi.org/10.1186/s13073-015-0138-2
- [4] Wainschtein, P., Jain, D., Zheng, Z., TOPMed Anthropometry Working Group,
 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Cupples,
 L.A., Shadyab, A.H., McKnight, B., Shoemaker, B.M., Mitchell, B.D., Psaty,
 B.M., Kooperberg, C., et al.: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data 54, 263–273 (2022)
 https://doi.org/10.1038/s41588-021-00997-7
- [5] Kosmicki, J.A., Churchhouse, C.L., Rivas, M.A., Neale, B.M.: Discovery of rare
 variants for complex phenotypes. Hum. Genet. 135, 625–634 (2016) https://doi.
 org/10.1007/s00439-016-1679-1
- [6] Fiziev, P.P., McRae, J., Ulirsch, J.C., Dron, J.S., Hamp, T., Yang, Y., Wainschtein, P., Ni, Z., Schraiber, J.G., Gao, H., Cable, D., Field, Y., Aguet, F., Fasnacht, M., Metwally, A., Rogers, J., Marques-Bonet, T., Rehm, H.L., O'Donnell-Luria, A., Khera, A.V., Farh, K.K.-H.: Rare penetrant mutations confer severe risk of common diseases. Science **380**, 1131 (2023) https://doi.org/10. 1126/science.abo1131
- [7] Hoogmartens, J., Cacace, R., Van Broeckhoven, C.: Insight into the genetic etiology of alzheimer's disease: A comprehensive review of the role of rare variants
 13, 12155 (2021) https://doi.org/10.1002/dad2.12155
- [8] Li, Z., Li, X., Zhou, H., Gaynor, S.M., Selvaraj, M.S., Arapoglou, T., Quick, C.,
 Liu, Y., Chen, H., Sun, R., et al.: A framework for detecting noncoding rarevariant associations of large-scale whole-genome sequencing studies 19, 1599–1611
 (2022) https://doi.org/10.1038/s41592-022-01640-x
- [9] Lee, S., Abecasis, G.R., Boehnke, M., Lin, X.: Rare-variant association analysis:
 study designs and statistical tests. Am. J. Hum. Genet. 95, 5–23 (2014) https:
 //doi.org/10.1016/j.ajhg.2014.06.009
- [10] Li, X., Li, Z., Zhou, H., Gaynor, S.M., Liu, Y., Chen, H., Sun, R., Dey, R., Arnett, D.K., Aslibekyan, S., et al.: Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large wholegenome sequencing studies at scale 52, 969–983 (2020) https://doi.org/10.1038/ s41588-020-0676-4
- [11] Clarke, B., Holtkamp, E., Öztürk, H., Mück, M., Wahlberg, M., Meyer, K.,
 Munzlinger, F., Brechtmann, F., Hölzlwimmer, F.R., Gagneur, J., Stegle, O.:

Integration of variant annotations using deep set networks boosts rare variant association genetics, 2023–0712548506 (2023) https://doi.org/10.1101/2023.07. 12.548506

- [12] Wagner, N., Çelik, M.H., Hölzlwimmer, F.R., Mertes, C., Prokisch, H., Yépez,
 V.A., Gagneur, J.: Aberrant splicing prediction across human tissues 55, 861–870
 (2023) https://doi.org/10.1038/s41588-023-01373-3
- ⁵²⁴ [13] Zeng, T., Li, Y.I.: Predicting RNA splicing from DNA sequence using pangolin ⁵²⁵ **23**, 103 (2022) https://doi.org/10.1186/s13059-022-02664-4
- [14] Avsec, Agarwal, V., Visentin, D., Ledsam, J.R., Grabska-Barwinska, A., Taylor,
 K.R., Assael, Y., Jumper, J., Kohli, P., Kelley, D.R.: Effective gene expression
 prediction from sequence by integrating long-range interactions. Nat. Methods
 18, 1196–1203 (2021) https://doi.org/10.1038/s41592-021-01252-x
- [15] Pollard, K.S., Hubisz, M.J., Rosenbloom, K.R., Siepel, A.: Detection of nonneutral substitution rates on mammalian phylogenies 20, 110–121 (2010) https: //doi.org/10.1101/gr.097857.109
- [16] Ionita-Laza, I., McCallum, K., Xu, B., Buxbaum, J.D.: A spectral approach integrating functional genomic annotations for coding and noncoding variants 48, 214–220 (2016) https://doi.org/10.1038/ng.3477
- [17] Skene, N.G., Grant, S.G.N.: Identification of vulnerable cell types in major
 brain disorders using single cell transcriptomes and expression weighted cell type
 enrichment 10, 16 (2016) https://doi.org/10.3389/fnins.2016.00016
- [18] Li, Z., Li, X., Liu, Y., Shen, J., Chen, H., Zhou, H., Morrison, A.C., Boerwinkle,
 E., Lin, X.: Dynamic scan procedure for detecting rare-variant association regions
 in whole-genome sequencing studies. Am. J. Hum. Genet. 104, 802–814 (2019)
 https://doi.org/10.1016/j.ajhg.2019.03.002
- ⁵⁴³ [19] Sey, N.Y.A., Hu, B., Mah, W., Fauni, H., McAfee, J.C., Rajarajan, P., Bren⁵⁴⁴ nand, K.J., Akbarian, S., Won, H.: A computational tool (H-MAGMA) for
 ⁵⁴⁵ improved prediction of brain-disorder risk genes by incorporating brain chromatin
 ⁵⁴⁶ interaction profiles. Nat. Neurosci. 23, 583–593 (2020) https://doi.org/10.1038/
 ⁵⁴⁷ s41593-020-0603-0
- [20] Ma, S., Dalgleish, J., Lee, J., Wang, C., Liu, L., Gill, R., Buxbaum, J.D., Chung,
 W.K., Aschard, H., Silverman, E.K., Cho, M.H., He, Z., Ionita-Laza, I.: Powerful
 gene-based testing by integrating long-range chromatin interactions and knockoff
 genotypes 118 (2021) https://doi.org/10.1073/pnas.2105191118
- ⁵⁵² [21] Zhang, S., Moll, T., Rubin-Sigler, J., Tu, S., Li, S., Yuan, E., Liu, M., Butt, A.,
 ⁵⁵³ Harvey, C., et al.: Deep learning modeling of rare noncoding genetic variants in
 ⁵⁵⁴ human motor neurons defines *CCDC146* as a therapeutic target for ALS (2024)
 - 19

555 https://doi.org/10.1101/2024.03.30.24305115

- ⁵⁵⁶ [22] Fulco, C.P., Nasser, J., Jones, T.R., Munson, G., Bergman, D.T., Subrama-⁵⁵⁷ nian, V., Grossman, S.R., Anyoha, R., Doughty, B.R., Patwardhan, *et al.*:
 ⁵⁵⁸ Activity-by-contact model of enhancer-promoter regulation from thousands of ⁵⁵⁹ CRISPR perturbations. Nat. Genet. **51**, 1664–1669 (2019) https://doi.org/10. ⁵⁶⁰ 1038/s41588-019-0538-0
- [23] Hoffman, M.D., Blei, D.M., Wang, C., Paisley, J.: Stochastic variational inference.
 J. Mach. Learn. Res. (2013)
- Jaganathan, K., Kyriazopoulou Panagiotopoulou, S., McRae, J.F., Darbandi,
 S.F., Knowles, D., Li, Y.I., Kosmicki, J.A., Arbelaez, J., Cui, W., Schwartz,
 G.B., Chow, E.D., Kanterakis, E., Gao, H., Kia, A., Batzoglou, S., Sanders, S.J.,
 Farh, K.K.-H.: Predicting splicing from primary sequence with deep learning 176,
 535–54824 (2019) https://doi.org/10.1016/j.cell.2018.12.015
- ⁵⁶⁸ [25] Madsen, B.E., Browning, S.R.: A groupwise association test for rare mutations
 ⁵⁶⁹ using a weighted sum statistic. PLoS Genet. 5, 1000384 (2009) https://doi.org/
 ⁵⁷⁰ 10.1371/journal.pgen.1000384
- ⁵⁷¹ [26] Morgenthaler, S., Thilly, W.G.: A strategy to discover genes that carry multi⁵⁷² allelic or mono-allelic risk for common diseases: a cohort allelic sums test (CAST)
 ⁵⁷³ **615**, 28–56 (2007) https://doi.org/10.1016/j.mrfmmm.2006.09.003
- ⁵⁷⁴ [27] He, Z., Xu, B., Lee, S., Ionita-Laza, I.: Unified sequence-based association tests
 ⁵⁷⁵ allowing for multiple functional annotations and meta-analysis of noncoding variation in metabochip data 101, 340–352 (2017) https://doi.org/10.1016/j.ajhg.
 ⁵⁷⁷ 2017.07.011
- ⁵⁷⁸ [28] Nott, A., Holtman, I.R., Coufal, N.G., Schlachetzki, J.C.M., Yu, M., Hu, R., Han,
 ⁵⁷⁹ C.Z., Pena, M., Xiao, J., Wu, *et al.*: Brain cell type-specific enhancer-promoter
 ⁵⁸⁰ interactome maps and disease-risk association. Science **366**, 1134–1139 (2019)
 ⁵⁸¹ https://doi.org/10.1126/science.aay0793
- [29] Dempster, E.R., Lerner, I.M.: Heritability of threshold characters 35, 212–236
 (1950) https://doi.org/10.1093/genetics/35.2.212
- [30] Zhou, X., Chen, Y., Ip, F.C.F., Jiang, Y., Cao, H., Lv, G., Zhong, H., Chen, J.,
 Ye, T., Chen, *et al.*: Deep learning-based polygenic risk analysis for alzheimer's disease prediction. Commun. Med. (Lond.) 3, 49 (2023) https://doi.org/10.1038/
 s43856-023-00269-x
- [31] Blei, D.M., Kucukelbir, A., McAuliffe, J.D.: Variational inference: A review for statisticians. J. Am. Stat. Assoc. 112, 859–877 (2017) https://doi.org/10.1080/ 01621459.2017.1285773

- [32] Gopinath, A., Collins, A., Khoshbouei, H., Streit, W.J.: Microglia and other
 myeloid cells in central nervous system health and disease. J. Pharmacol. Exp.
 Ther. 375, 154–160 (2020) https://doi.org/10.1124/jpet.120.265058
- [33] Gratuze, M., Leyns, C.E.G., Holtzman, D.M.: New insights into the role of TREM2 in alzheimer's disease. Mol. Neurodegener. 13, 66 (2018) https://doi. org/10.1186/s13024-018-0298-9
- [34] Han, Y., Chen, K., Yu, H., Cui, C., Li, H., Hu, Y., Zhang, B., Li, G.: Maf1 loss regulates spinogenesis and attenuates cognitive impairment in alzheimer's disease.
 Brain 147, 2128–2143 (2024) https://doi.org/10.1093/brain/awae015
- [35] Bottero, V., Potashkin, J.A.: Meta-analysis of gene expression changes in
 the blood of patients with mild cognitive impairment and alzheimer's disease
 dementia. Int. J. Mol. Sci. 20, 5403 (2019) https://doi.org/10.3390/ijms20215403
- [36] Izadi, F., Soheilifar, M.H.: Exploring potential biomarkers underlying patho genesis of alzheimer's disease by differential co-expression analysis 10, 233–241
 (2018)
- [37] Xiao, B., Kuang, Z., Zhang, W., Hang, J., Chen, L., Lei, T., He, Y., Deng,
 C., Li, W., Lu, J., Qu, J., et al.: Glutamate ionotropic receptor kainate type
 subunit 3 (GRIK3) promotes epithelial-mesenchymal transition in breast cancer cells by regulating SPDEF/CDH1 signaling 58, 1314–1323 (2019) https:
 //doi.org/10.1002/mc.23014
- [38] Spead, O., Zaepfel, B.L., Rothstein, J.D.: Nuclear pore dysfunction in neurode generation. Neurotherapeutics 19, 1050–1060 (2022) https://doi.org/10.1007/
 s13311-022-01293-w
- [39] Bukvic, N., De Rinaldis, M., Chetta, M., Trabacca, A., Bassi, M.T., Marsano,
 R.M., Holoubkova, L., Rivieccio, M., Oro, M., Resta, *et al.*: De novo pathogenic
 variant in FBRSL1, non OMIM gene paralogue AUTS2, causes a novel recognizable syndromic manifestation with intellectual disability; an additional patient
 and review of the literature. Genes (Basel) 15, 826 (2024) https://doi.org/10.
 3390/genes15070826
- [40] Mishra, R., Li, B.: The application of artificial intelligence in the genetic study of
 alzheimer's disease. Aging Dis. 11, 1567–1584 (2020) https://doi.org/10.14336/
 AD.2020.0312
- [41] Lutz, M.W., Sprague, D., Barrera, J., Chiba-Falek, O.: Shared genetic etiology underlying alzheimer's disease and major depressive disorder. Transl. Psychiatry 10, 88 (2020) https://doi.org/10.1038/s41398-020-0769-y
- ⁶²⁶ [42] GTEx Consortium: The GTEx consortium atlas of genetic regulatory effects across human tissues **369**, 1318–1330 (2020) https://doi.org/10.1126/science.

628 aaz1776

[43] Humphrey, J., Brophy, E., Kosoy, R., Zeng, B., Coccia, E., Mattei, D., Ravi,
 A., Efthymiou, A.G., Navarro, E., Muller, B.Z., et al.: Long-read RNA-seq atlas
 of novel microglia isoforms elucidates disease-associated genetic regulation of
 splicing. medRxiv, 2023–120123299073 (2023) https://doi.org/10.1101/2023.12.
 01.23299073

- [44] Bellenguez, C., Küçükali, F., Jansen, I.E., Kleineidam, L., Moreno-Grau, S.,
 Amin, N., Naj, A.C., Campos-Martin, R., Grenier-Boley, B., Andrade, *et al.*: New
 insights into the genetic etiology of alzheimer's disease and related dementias.
 Nat. Genet. 54, 412–436 (2022) https://doi.org/10.1038/s41588-022-01024-z
- [45] Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStafano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, *et al.*: Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for alzheimer's disease. Nat. Genet. 45, 1452–1458 (2013) https://doi.org/10.1038/
 ng.2802
- [46] Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S.,
 ⁶⁴⁴ Chang, D., Tan, M., Kia, D.A., Noyce, A.J., *et al.*: Identification of novel risk
 ⁶⁴⁵ loci, causal insights, and heritable risk for parkinson's disease: a meta-analysis
 ⁶⁴⁶ of genome-wide association studies. Lancet Neurol. 18, 1091–1102 (2019) https:
 ⁶⁴⁷ //doi.org/10.1016/S1474-4422(19)30320-5
- [47] Desikan, R.S., Schork, A.J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L.K.,
 ⁶⁴⁹ Holland, D., Brewer, J.B., Chen, C.-H., Thompson, W.K., *et al.*: Genetic overlap
 ⁶⁵⁰ between alzheimer's disease and parkinson's disease at the MAPT locus. Mol.
 ⁶⁵¹ Psychiatry **20**, 1588–1595 (2015) https://doi.org/10.1038/mp.2015.6
- [48] Kuksa, P.P., Liu, C.-L., Fu, W., Qu, L., Zhao, Y., Katanic, Z., Clark, K., Kuzma,
 A.B., Ho, P.-C., *et al.*: Alzheimer's disease variant portal: A catalog of genetic
 findings for alzheimer's disease. J. Alzheimers. Dis. 86, 461–477 (2022) https:
 //doi.org/10.3233/JAD-215055
- [49] Wu, M.C., Lee, S., Cai, T., Li, Y., Boehnke, M., Lin, X.: Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum.
 Genet. 89, 82–93 (2011) https://doi.org/10.1016/j.ajhg.2011.05.029
- [50] Lee, S., Emond, M.J., Bamshad, M.J., Barnes, K.C., Rieder, M.J., Nickerson,
 D.A., NHLBI GO Exome Sequencing Project—ESP Lung Project Team, Christiani, D.C., Wurfel, M.M., Lin, X.: Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies 91, 224–237 (2012) https://doi.org/10.1016/j.ajhg.2012.06.
 007
- ⁶⁶⁵ [51] Liu, Y., Chen, S., Li, Z., Morrison, A.C., Boerwinkle, E., Lin, X.: ACAT: A fast

- and powerful p value combination method for rare-variant analysis in sequencing studies **104**, 410–421 (2019) https://doi.org/10.1016/j.ajhg.2019.01.002
- [52] Beecham, G.W., Bis, J.C., Martin, E.R., Choi, S.-H., DeStefano, A.L., Duijn,
 C.M., Fornage, M., Gabriel, S.B., Koboldt, D.C., Larson, D.E., *et al.*: The
 alzheimer's disease sequencing project: Study design and sample selection. Neurol
 Genet 3, 194 (2017) https://doi.org/10.1212/NXG.00000000000194
- [53] Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M., Chen, W.-M.:
 Robust relationship inference in genome-wide association studies 26, 2867–2873
 https://doi.org/10.1093/bioinformatics/btq559
- ⁶⁷⁵ [54] Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A.R., Bender, D.,
 ⁶⁷⁶ Maller, J., Sklar, P., Bakker, P.I.W., Daly, M.J., Sham, P.C.: PLINK: a tool set
 ⁶⁷⁷ for whole-genome association and population-based linkage analyses 81, 559–575
 ⁶⁷⁸ (2007) https://doi.org/10.1086/519795
- 679 [55] Siva, N.: 1000 genomes project **26**, 256 (2008) https://doi.org/10.1038/ 680 nbt0308-256b
- [56] Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., Smoller, J.W.: Polygenic prediction
 via bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776
 (2019) https://doi.org/10.1038/s41467-019-09718-5
- [57] Eli, B., Jonathan, P.C., Martin, J., Fritz, O., Neeraj, P., Theofanis, K., Rohit, S.,
 Paul, S., Paul, H., Noah, D.G.: Pyro: Deep universal probabilistic programming.
 arXiv [cs.LG] (2018) https://doi.org/10.48550/arXiv.1810.09538
- Liu, X., White, S., Peng, B., Johnson, A.D., Brody, J.A., Li, A.H., Huang, Z.,
 Carroll, A., Wei, P., Gibbs, R., Klein, R.J., Boerwinkle, E.: WGSA: an annotation
 pipeline for human genome sequencing studies 53, 111–112 (2016) https://doi.
 org/10.1136/jmedgenet-2015-103423
- [59] Bernstein, B.E., Stamatoyannopoulos, J.A., Costello, J.F., Ren, B., Milosavljevic,
 A., Meissner, A., Kellis, M., Marra, M.A., Beaudet, A.L., Ecker, J.R., et al.: The NIH roadmap epigenomics mapping consortium 28, 1045–1048 (2010) https: //doi.org/10.1038/nbt1010-1045
- [60] Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q.,
 Alföldi, J., Watts, N.A., Vittal, C., Gauthier, L.D., *et al.*: A genomic mutational
 constraint map using variation in 76,156 human genomes. Nature 625, 92–100
 (2024) https://doi.org/10.1038/s41586-023-06045-0
- [61] Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang,
 Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., Gauthier, *et al.*:
 The mutational constraint spectrum quantified from variation in 141,456 humans.
 Nature 581, 434–443 (2020) https://doi.org/10.1038/s41586-020-2308-7
 - 23

[62] Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S.,
Schoech, A.P., Geijn, B., Reshef, Y., Márquez-Luna, C., O'Connor, L., Pirinen,
M., Finucane, H.K., Price, A.L.: Functionally informed fine-mapping and polygenic localization of complex trait heritability. Nat Genet 52, 1355–1363 (2020)
https://doi.org/10.1038/s41588-020-00735-5

- [63] Szustakowski, J.D., Balasubramanian, S., Kvikstad, E., Khalid, S., Bronson,
 P.G., Sasson, A., Wong, E., Liu, D., Wade Davis, J., Haefliger, *et al.*: Advancing human genetics research and drug discovery through exome sequencing
 of the UK biobank. Nat Genet 53, 942–948 (2021) https://doi.org/10.1038/
 s41588-021-00885-0
- [64] Zhou, W., Zhao, Z., Nielsen, J.B., Fritsche, L.G., LeFaive, J., Gagliano Taliun,
 S.A., Bi, W., Gabrielsen, M.E., Daly, M.J., Neale, B.M., et al.: Scalable generalized linear mixed model for region-based association tests in large biobanks and
 cohorts 52, 634–639 (2020) https://doi.org/10.1038/s41588-020-0621-6
- [65] Londhe, S., Lindner, J., Chen, Z., Holtkamp, E., Hölzlwimmer, F.R., Casale, F.P.,
 Brechtmann, F., Gagneur, J.: Functional gene embeddings improve rare variant
- ⁷¹⁹ polygenic risk scores. bioRxiv, 2024–0722604535 (2024) https://doi.org/10.1101/
- 720 2024.07.22.604535